原发部位、MYC/Bcl-2 双表达和重排对接受联合治疗的早期弥漫性大 B 细胞淋巴瘤患者疾病复发的影响。

The impact of cell-of-origin, MYC/Bcl-2 dual expression and rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.

机构信息

Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leuk Lymphoma. 2021 Jun;62(6):1361-1369. doi: 10.1080/10428194.2020.1869965. Epub 2021 Jan 22.

DOI:10.1080/10428194.2020.1869965

PMID:33480830

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8262455/

Abstract

We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL) treated with consolidative radiation therapy (RT) after a metabolic complete response to immunochemotherapy. With a median follow-up of 31.1 months (95% CI 27.4 - 34.8), 4 relapses occurred. The 3-year progression free survival (PFS), overall survival (OS), and loco-regional relapse free survival (LRFS) for the cohort were 95%, 96%, and 100%, respectively. There were no differences in OS, PFS, or LRFS based on COO or MYC/Bcl-2 dual expression (DE). Similarly, patients with translocations without or rearrangements did not have worse outcomes. Consolidative RT produced excellent local control, regardless of DLBCL biology, with one late in-field failure.

摘要

我们研究了 111 例局限期弥漫性大 B 细胞淋巴瘤（DLBCL）患者在免疫化疗达到代谢完全缓解后接受巩固性放疗（RT）后的细胞起源（COO）、MYC 和 Bcl-2 过表达以及孤立重排对预后的影响。中位随访 31.1 个月（95%CI 27.4-34.8），有 4 例复发。该队列的 3 年无进展生存（PFS）、总生存（OS）和局部区域无复发生存（LRFS）分别为 95%、96%和 100%。COO 或 MYC/Bcl-2 双重表达（DE）与 OS、PFS 或 LRFS 无差异。同样，无或重排的患者也没有更差的结局。无论 DLBCL 生物学如何，巩固性 RT 均能产生极好的局部控制效果，仅有 1 例晚场失败。